Sugi Predict

Sugi Predict / Targets / STAT4

STAT4

Signal transducer and activator of transcription 4 · Q14765 · STAT4 on Sugi Atlas →

2,396 patent compounds predicted against STAT4, 1,993 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL22468769 SCHEMBL22468769 1.00 1/20
SCHEMBL22468771 SCHEMBL22468771 1.00 1/20
SCHEMBL25210237 SCHEMBL25210237 1.00 1/20
SCHEMBL25210244 SCHEMBL25210244 1.00 1/20
SCHEMBL25199341 SCHEMBL25199341 0.99 1/20
SCHEMBL25217106 SCHEMBL25217106 0.97 1/20
SCHEMBL25217109 SCHEMBL25217109 0.97 1/20
SCHEMBL25193680 SCHEMBL25193680 0.91 1/20
SCHEMBL22468627 SCHEMBL22468627 0.89 1/20
SCHEMBL22468628 SCHEMBL22468628 0.89 1/20
SCHEMBL25197649 SCHEMBL25197649 0.88 1/20
SCHEMBL25200222 SCHEMBL25200222 0.88 1/20
SCHEMBL25212617 SCHEMBL25212617 0.88 1/20
SCHEMBL25212621 SCHEMBL25212621 0.88 1/20
SCHEMBL22468638 SCHEMBL22468638 0.88 1/20
SCHEMBL22468642 SCHEMBL22468642 0.88 1/20
SCHEMBL25197093 SCHEMBL25197093 0.88 1/20
SCHEMBL22468640 SCHEMBL22468640 0.87 1/20
SCHEMBL22468641 SCHEMBL22468641 0.87 1/20
SCHEMBL25197911 SCHEMBL25197911 0.87 1/20

Clinical trials — most relevant to STAT4 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Safety and Efficacy of Tofacitinib in the Treatment of NSAID Refractory Axial Spondyloarthritis:A Clinical Trial PHASE2/PHASE3UNKNOWN
Effect of Baricitinib Treatment on Peripheral Bone in RA PHASE3UNKNOWN
Dual JAK1/TYK2 Inhibitor for Cicatricial Alopecia PHASE2COMPLETED
Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma PHASE2COMPLETED
Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation PHASE1/PHASE2COMPLETED
A Study Testing Emactinib Sulfate With Chemotherapy and Immunotherapy Before Surgery for Advanced Head and Neck Cancer PHASE2RECRUITING
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients PHASE1RECRUITING
Itacitinib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis PHASE1COMPLETED
In Vitro Evaluation of a Novel Drug on Airway Epithelial Cells Obtained From Participants With Severe Asthma EARLY_PHASE1COMPLETED
Immune Interactions in Severe Asthma nanCOMPLETED
Cutaneous JAK in Vitiligo and Acne Vulgaris. nanUNKNOWN
STAT4 in Multiple Sclerosis by PCR and Flow Cytometry nanCOMPLETED
Immunoassay and Regulation of Traditional Chinese Medicine on Cancer Patients nanUNKNOWN
Gene Expression Of Suppressor Of Cytokines in In Cutaneous Warts nanCOMPLETED
Androgenetic Alopecia and the JAK-STAT Pathway nanCOMPLETED
Deep Phenotyping of Cutaneous Lupus Erythematosus nanUNKNOWN
Recombinant Interferon Alfa-2b in Treating Patients With Melanoma nanCOMPLETED
Regulation of the Immune System in Response to the Treatment With Tocilizumab in Rheumatoid Arthritis Patients nanCOMPLETED
Evaluation Safety ,Efficacy Baricitinib Plus Excimer Light Versus Excimer Light Alone in Non Segmental Vitiligo nanUNKNOWN
Impact of Vorinostat on Pruritus Signaling Pathways - Merck Study nanWITHDRAWN
Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia nanUNKNOWN
Levels of the Stat4 Alpha and Stat4 Beta Isoforms in PBMCs From Patients With Crohn's Disease and Ulcerative Colitis nanCOMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN
CircularRNA-microRNA-mRNA Regulatory Axis in IVF nanNOT_YET_RECRUITING
Prospective Observational Study Evaluating the Safety and Efficacy of Immunomodulatory Therapies in Refractory Inflammatory and Autoimmune Diseases nanNOT_YET_RECRUITING
Prohepcidin, Inflammation and Iron Homeostasis in Hemodialysis Patients With Chronic Hepatitis C nanCOMPLETED
Study the Content of the HBV DNA in Liver Biopsy in the Patients Chronic Hepatitis Delta nanUNKNOWN
Effect of Different Therapeutic Strategies on Regulatory T Cells in Kidney Transplantation nanCOMPLETED
Zn Supplementation in HIV Immunological Non Responders nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a STAT4 binder may also engage these)

ProteinNameSimilarity
P42228 — 1.000 P42228 →
A2AF47 — 0.985 A2AF47 →
DOCK11 Dedicator of cytokinesis protein 11 0.983 landscape →
P42225 — 0.979 P42225 →
P31266 — 0.979 P31266 →
Q8N1I0 — 0.978 Q8N1I0 →
Q91WS7 — 0.977 Q91WS7 →
Q5RFK6 — 0.977 Q5RFK6 →
Q5RHQ8 — 0.977 Q5RHQ8 →
Q5FWH3 — 0.977 Q5FWH3 →
Q5R8B7 — 0.976 Q5R8B7 →
Q8BYR5 — 0.976 Q8BYR5 →
Q6NX27 — 0.976 Q6NX27 →
Q96BY6 — 0.976 Q96BY6 →
Q8BYZ7 — 0.976 Q8BYZ7 →
B0R034 — 0.976 B0R034 →
Q3SZ41 — 0.976 Q3SZ41 →
Q6EDY6 — 0.976 Q6EDY6 →
NIBAN2 Protein Niban 2 0.976 landscape →
Q91880 — 0.976 Q91880 →
Q5R5N9 — 0.976 Q5R5N9 →
Q499U2 — 0.976 Q499U2 →
Q80TJ1 — 0.975 Q80TJ1 →
Q8K0Q5 — 0.975 Q8K0Q5 →
Q9VPB1 — 0.975 Q9VPB1 →
Q5R5R4 — 0.975 Q5R5R4 →
Q5R8M5 — 0.974 Q5R8M5 →
Q8N1G2 — 0.974 Q8N1G2 →
Q15111 — 0.974 Q15111 →
Q6GLR7 — 0.974 Q6GLR7 →